Enigma–CDH18 Companion Diagnostics for CDK4 Inhibitor Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK4 inhibitor therapies for cancers like liposarcoma, ER-positive HER2-negative breast cancer, lung cancer, multiple myeloma, and glioblastoma face uncertainty in patient responsiveness due to unpredictable therapeutic outcomes, despite genetic pre-screening, necessitating improved predictive biomarkers.
Innovation Solution
Utilization of Enigma and Cadherin 18 (CDH18) as biomarkers to identify cancer cells likely to undergo effective cellular senescence upon CDK4 inhibitor treatment, based on the localization of these proteins to foci within cells and higher expression levels, guiding personalized treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genetic pre-screening is performed for CDK4 inhibitor therapy, then patient selection is improved, but predictive accuracy of treatment response remains insufficient
Solution Approach 1:
The patent transitions from genetic parameter screening (CDK4 amplification, Rb expression) to protein expression and localization parameters (Enigma and CDH18 levels and foci formation). This parameter change enables more accurate prediction of treatment response by measuring actual protein presence and cellular senescence markers rather than relying solely on genetic predisposition.
Solution Approach 2:
Enigma and CDH18 proteins serve as intermediary biomarkers that mediate between CDK4 inhibition and cellular senescence outcomes. These intermediaries provide a mechanistic link that explains why certain patients respond to treatment, bridging the gap between drug administration and therapeutic effect prediction.
2Productivity
If CDK4 inhibitor therapy is administered broadly, then more patients may benefit, but many patients receive ineffective treatment
Solution Approach 1:
The patent implements preliminary diagnostic testing for Enigma and CDH18 protein expression and foci formation before initiating CDK4 inhibitor therapy. This preliminary action identifies patients most likely to respond, ensuring that treatment is started only in appropriate candidates and avoiding wasteful administration to non-responders.
Solution Approach 2:
The diagnostic assay provides feedback on cellular senescence capacity through Enigma and CDH18 measurements, allowing clinicians to adjust treatment decisions based on predicted response. This feedback loop prevents ineffective treatment by identifying non-responders before therapy begins.
Data Source
AI summary
The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. Accordingly, in certain non-limiting embodiments, the present invention provides for methods, compositions and kits for a companion diagnostic for CDK4 inhibitors, and in particular, for the use of the colocalization of Enigma and CDH18 biomarkers to foci within the cancer for determining whether the cancer can be successfully treated by CDK4 inhibition.